Related Experiment Video
Updated: Sep 12, 2025
05:31
Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
3.0K
Adult Transcatheter Pulmonary Valve Replacement.
Amha Weldehana1, Beeletsega Yeneneh2, Samrawit Zewde3
1From the Department of Cardiology, Westchester Medical Center, Valhalla, NY.
Cardiology in Review
|August 7, 2025
Summary
Transcatheter pulmonary valve replacement (TPVR) offers a less invasive alternative to surgery for pulmonary valve issues. While effective with a 95% survival rate, it carries risks like infective endocarditis.
Area of Science:
- Cardiovascular Interventions
- Structural Heart Disease
- Pulmonary Valve Disease
Background:
- Transcatheter pulmonary valve replacement (TPVR) has emerged as a significant structural intervention over the last 25 years.
- It serves as an alternative to surgical pulmonary valve replacement (SPVR) for patients with moderate to severe pulmonary stenosis and regurgitation.
Purpose of the Study:
- To review the indications, procedural complexities, and outcomes of transcatheter pulmonary valve replacement (TPVR).
- To compare TPVR with surgical pulmonary valve replacement (SPVR) regarding efficacy, complications, and survival rates.
Main Methods:
- Review of current literature on transcatheter pulmonary valve replacement (TPVR) procedures.
- Analysis of indications, including congenital pulmonary stenosis, RVOT obstruction, and bioprosthetic valve dysfunction.
- Discussion of procedural steps, device deployment, and potential complications.
Main Results:
- Limited studies indicate a 95% survival rate for TPVR.
- TPVR shows similar reintervention rates and no mortality difference compared to SPVR.
- Increased risk of infective endocarditis and potentially higher costs are associated with TPVR.
Conclusions:
- Transcatheter pulmonary valve replacement (TPVR) is a viable option for specific pulmonary valve pathologies.
- While offering comparable mortality to SPVR, vigilance for infective endocarditis and cost-effectiveness is necessary.
